Last reviewed · How we verify
Glucagon Nasal Powder
Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.
Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Severe hypoglycemia in patients with diabetes.
At a glance
| Generic name | Glucagon Nasal Powder |
|---|---|
| Also known as | LY900018 |
| Sponsor | Eli Lilly and Company |
| Drug class | Glucagon receptor agonist |
| Target | Glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Glucagon is a peptide hormone that activates glucagon receptors on liver cells, triggering the breakdown of stored glycogen into glucose and promoting the synthesis of new glucose from precursors. This nasal powder formulation allows rapid non-injectable delivery for emergency treatment of severe hypoglycemia. The intranasal route provides faster absorption and easier administration compared to traditional intramuscular injection in acute settings.
Approved indications
- Severe hypoglycemia in patients with diabetes
Common side effects
- Nausea
- Vomiting
- Headache
- Hyperglycemia
Key clinical trials
- A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes (PHASE1)
- Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia (PHASE3)
- A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus (PHASE3)
- Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia (PHASE2)
- Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucagon Nasal Powder CI brief — competitive landscape report
- Glucagon Nasal Powder updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI